Literature DB >> 15837215

A truncated ORF2 protein contains the most immunogenic site on ORF2: antibody responses to non-vaccine sequences following challenge of vaccinated and non-vaccinated macaques with hepatitis E virus.

Yi-Hua Zhou1, Robert H Purcell, Suzanne U Emerson.   

Abstract

A candidate hepatitis E vaccine is composed of amino acids (aa) 112-607 of the 660-aa protein encoded by open reading frame 2 (ORF2) of hepatitis E virus (HEV). We have studied the antibody response to vaccine-associated epitopes and to epitopes excluded from the vaccine to determine if important epitopes were omitted from the vaccine and if antibody responses to these regions could be used to differentiate between infection and vaccination. ELISAs were developed based on genotype 1 ORF2 peptides, containing aa 112-607 (vaccine), 458-607 (minimum neutralization site), 1-111 (N-terminus) and 607-660 (C-terminus), as well as on ORF3 peptides, containing aa 1-123 (complete) and 91-123 (C-terminus). All naive macaques infected with HEV genotype 1, 2, 3 or 4 produced antibodies to all ORF2 peptides. Anti-ORF3 was detected in both monkeys infected with genotype 1 virus and in one of two infected with genotype 2 virus. These antibody responses were considerably weaker than those directed against the neutralization site. In contrast, vaccinated animals that were challenged with HEV had a diminished or absent immune response to the peptides not included in the vaccine. Thus, only minor epitopes were excluded from the vaccine; they had limited utility for distinguishing between vaccination and infection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15837215     DOI: 10.1016/j.vaccine.2004.12.020

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  24 in total

Review 1.  Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins.

Authors:  Xiao Zhang; Lu Xin; Shaowei Li; Mujin Fang; Jun Zhang; Ningshao Xia; Qinjian Zhao
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 2.  Development of new hepatitis E vaccines.

Authors:  Yufeng Cao; Zhenhong Bing; Shiyu Guan; Zecai Zhang; Xinping Wang
Journal:  Hum Vaccin Immunother       Date:  2018-06-18       Impact factor: 3.452

3.  Chimeric hepatitis E virus-like particle as a carrier for oral-delivery.

Authors:  Pitchanee Jariyapong; Li Xing; Nienke E van Houten; Tian-Cheng Li; Wattana Weerachatyanukul; Benjamin Hsieh; Carlos G Moscoso; Chun-Chieh Chen; Masahiro Niikura; R Holland Cheng
Journal:  Vaccine       Date:  2012-10-26       Impact factor: 3.641

4.  Establishment of a Highly Sensitive Assay for Detection of Hepatitis E Virus-Specific Immunoglobulins.

Authors:  Gérard Krause; Claudia Sievers; Katrin Bohm; Julia Strömpl; Andi Krumbholz; Roland Zell
Journal:  J Clin Microbiol       Date:  2020-01-28       Impact factor: 5.948

Review 5.  Hepatitis E Virus Genome Structure and Replication Strategy.

Authors:  Scott P Kenney; Xiang-Jin Meng
Journal:  Cold Spring Harb Perspect Med       Date:  2019-01-02       Impact factor: 6.915

6.  Assessment of the cross-protective capability of recombinant capsid proteins derived from pig, rat, and avian hepatitis E viruses (HEV) against challenge with a genotype 3 HEV in pigs.

Authors:  Brenton J Sanford; Tanja Opriessnig; Scott P Kenney; Barbara A Dryman; Laura Córdoba; Xiang-Jin Meng
Journal:  Vaccine       Date:  2012-08-17       Impact factor: 3.641

Review 7.  Autochthonous hepatitis e virus infections: a new transfusion-associated risk?

Authors:  Jens Dreier; David Juhl
Journal:  Transfus Med Hemother       Date:  2013-12-30       Impact factor: 3.747

8.  A truncated hepatitis E virus ORF2 protein expressed in tobacco plastids is immunogenic in mice.

Authors:  Yuan-Xiang Zhou; Maggie Yuk-Ting Lee; James Ming-Him Ng; Mee-Len Chye; Wing-Kin Yip; Sze-Yong Zee; Eric Lam
Journal:  World J Gastroenterol       Date:  2006-01-14       Impact factor: 5.742

Review 9.  Hepatitis E: Discovery, global impact, control and cure.

Authors:  Mohammad S Khuroo; Mehnaaz S Khuroo; Naira S Khuroo
Journal:  World J Gastroenterol       Date:  2016-08-21       Impact factor: 5.742

10.  Mutations within potential glycosylation sites in the capsid protein of hepatitis E virus prevent the formation of infectious virus particles.

Authors:  Judith Graff; Yi-Hua Zhou; Udana Torian; Hanh Nguyen; Marisa St Claire; Claro Yu; Robert H Purcell; Suzanne U Emerson
Journal:  J Virol       Date:  2007-11-21       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.